Q-omics provides the consensus-scored CDC42EP5 profile across patient tissues and cancer cell-line models. CDC42EP5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CDC42EP5 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CDC42EP5 protein abundance shows 21,580 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where CDC42EP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42EP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42EP5 survival associations across molecular data types. CDC42EP5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42EP5 RNA expression–survival associations across cancer types. High CDC42EP5 expression shows unfavorable associations in KIRP, LGG, LUAD, ESCA and LUSC, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRP as the clearest survival context for CDC42EP5 RNA expression.
This table summarizes CDC42EP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDC42EP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42EP5 shows lower tumor expression in KICH, UCEC and BRCA and higher tumor expression in THCA, KIRC and LIHC. The THCA box plot shows higher CDC42EP5 RNA expression in tumor versus normal tissue (log2 FC = +1.805, t-test p < 0.001).
This table shows molecular features associated with CDC42EP5 in patient tissues and cancer cell lines. In patient samples, CDC42EP5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42EP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
